OOIR: Observatory of International Research

Papers

(The TQCC of Leukemia Research is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Editorial Board	51
Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy	26
Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion	26
New treatments for adult T-cell leukemia/lymphoma	25
Long-term engraftment stability of umbilical cord blood cells preserved in −135 °C mechanical freezers	24
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)	23
Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation	21
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia	20
ALK INHIBITORS SAFETY PROFILE IN PEDIATRIC PATIENTS TREATED FOR AN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REAL LIFE EXPERIENCE AMONG A FRENCH COHORT	19
ALK INHIBITOR PLUS VINBLASTINE FOR REFRACTORY/RELAPSED PEDIATRIC ALK+ ANAPLASTIC LARGE CELL LYMPHOMA: A PROSPECTIVE, ONE-ARM, OPEN-LABEL REAL-WORLD STUDY	19
CLINICAL FEATURES AND TREATMENT OUTCOME OF CHILDREN WITH LYMPHOBLASTIC LYMPHOMA IN TAIWAN	17
ANAPLASTIC LYMPHOMA KINASE INHIBITION ACTIVATES AUTOPHAGY IN ALK+ ANAPLASTIC LARGE CELL LYMPHOMA	17
A CASE OF B-CELL LYMPHOBLASTIC LYMPHOMA WITH PRIMARY BONE INVOLVEMENT: A MIMICKER OF RHEUMATOLOGICAL AND INFECTIOUS DISEASE	16
We were in the fight together: The expectations of bereaved caregivers of patients with acute myeloid leukemia from diagnosis to death	15
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study	14
Editorial Board	13
Editorial Board	13
Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study	12
Editorial Board	11
How low can you go?: Methodologic considerations in clonal hematopoiesis variant calling	11
Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid	11
Impact of active surveillance at time of diagnosis on overall survival in nodular lymphocyte-predominant Hodgkin lymphoma: A National Cancer Database study	11
Editorial Board	11
Topic: AS02-Epidemiology: CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN A CHILEAN HEMATOLOGICAL REFERENCE CENTER	11
Editorial Board	11

Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): OPTIMIZATION OF MDS PATIENT-DERIVED XENOGRAFT (PDX) MODELS BY COMPARISON OF NSG AND NBSGW MICE	10
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: NEPHROTIC SYNDROME IN MDS: A CASE REPORT AND REVIEW OF THE LITERATURE	10
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS OF THE BONE MARROW NICHE CONTRIBUTE TO THE PROINFLAMMATORY PHENOTYPE OF CMML MONOCYTES TH	10
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: CALPROTECTIN (S100A8/A9) EFFECTS ON HEALTHY CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS ARE AMPLIFIED IN CHRONIC	10
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: THE GENE EXPRESSION PROFILE OF GENES BELONGING TO TRANSFORMING GROWTH FACTOR-B PATHWAY IS DEREGULATED IN SF3B1 MUTATED LOW-RIS	10
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: ALTERED DEVELOPMENTAL PATHWAYS OF INNATE LYMPHOID CELLS IN MYELODYSPLASTIC SYNDROMES CORRELATE DISEASE PROGNOSIS AND RE	10
Topic: AS04-MDS Biology and Pathogenesis/AS04g-Epigenetic deregulation: THE KEAP1-NRF2 REDOX PATHWAY CONTROLS THE SENSITIVITY OF MDS/AML CELLS TO AZACYTIDINE	10
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: DER(1;7)(Q10;P10) DEFINES A DISTINCT SUBTYPE OF MYELODYSPLASIA	10
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: HEMATOPOIETIC STEM CELLS OF LOWER-RISK MDS PATIENTS WITH RAPID PROGRESSION SHOW QUIESCENT-LIKE CELL STATE SIMILAR TO THAT OF H	10
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: HIGHER LEPTIN LEVEL IS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME: A COMPARATIVE STUDY	10
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINE DEAMINASE	9
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: HIGH BM PLASMA S100A8/A9 IS ASSOCIATED WITH A PERTURBED MICROENVIRONMENT AND POOR PROGNOSIS IN MYELODYSPLASTIC SYNDROMES	9
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)	9
Topic: AS07-Singular Entities/Subtypes/AS07d-MDS with ring sideroblasts: COEXISTENCE OF SF3B1 AND JAK2 EXON 25 MUTATION IN A PATIENT WITH MYELODYSPLASTIC SYNDROME PROGRESSING TO INV(3)(Q21Q26) ACUTE M	9
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS	9
Topic: AS08-Treatment/AS08a-Current treatment options - Higher risk MDS: SINGLE-CENTER EXPERIENCE OF AZACITIDINE-VENETOCLAX IN SECONDARY ACUTE MYELOID LEUKEMIA (AML), ARISING FROM MYELODYSPLASTIC SYND	9
ANTIBODY-BASED THERAPY OF MDS	8
CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES	8
GENETIC ORIGINS AND CLONAL TRAJECTORIES IN PEDIATRIC MYELODYSPLASTIC SYNDROMES	8
DISTINCT PATHOGENESIS OF CLONAL HEMATOPOIESIS REVEALED BY SINGLE-CELL MULTI-OMICS SEQUENCING	8
Topic: AS08-Treatment/AS08d-New developments – Preclinical studies: DEVELOPMENT OF APTAMERS AS THERAPY FOR CONGENITAL NEUTROPENIA DISEASES	8
MDS AND AUTO-IMMUNITY	8
PATIENT AVATARS TO GUIDE CLINICAL TRIALS IN CMML	8
5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES	8
Topic: AS01-Diagnosis/AS01a-Cytomorphology: ARTIFICIAL INTELLIGENCE MAY HELP THE HEMATOPATHOLOGIST IN EVALUATION OF BONE MASS AND CELLULARITY IN BONE MARROW SPECIMENS OF PATIENTS WITH MDS	8
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPEN	8
CH ASSOCIATED DISEASES	8
CURRENT TREATMENT OF MDS WITH DELETION 5Q	8
POST-AZACITIDINE CLONE SIZE PREDICTS LONG-TERM OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND RELATED MYELOID NEOPLASMS	8
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): APPLICATION OF THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-M) MODEL IN SOUTH-AMERICAN MDS PAT	8
Editorial Board	8
Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia	7
Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia	7
Topic: AS09-Quality of life-Disease experiences: EXPLORING UNMET NEEDS OF MDS PATIENTS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY	7
NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype	7
SURVIVAL OF PATIENTS WITH EXTRANODAL NK-CELL LYMPHOMA IN THE UNITED STATES	7
Topic: AS02-Epidemiology: THE EPIDEMIOLOGY OF MYELODYSPLASTIC SYNDROME (MDS) FROM ARMENIA, A RESOURCE-LIMITED COUNTRY	7
Anthracycline induced left ventricular dysfunction in AML: A focus on the molecularly defined future of cardio-oncology	7
Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis	7
Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM)	7
Editorial Board	7
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): UMBRELLA PROJECT: UNIFIED PLATFORM FOR A BETTER INTEGRAL EVALUATION OF MYELODYSPLASTIC SYNDROMES IN SPAIN	7
Topic: AS09-Quality of life-Disease experiences: LONGITUDINAL TRAJECTORY OF QUALITY OF LIFE IN MDS AND IMPACT OF PATIENT-RELATED FACTORS	7
Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis	7
BCR EXPRESSION IN BURKITT LYMPHOMA: NEW INSIGHT IN MUTATIONAL LANDSCAPE	7
Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemother	7
PROGNOSTIC VALUE OF INTERIM 18FDG-PET-CT IN MATURE B-CELL NON-HODGKIN LYMPHOMA	6
PEDIATRIC INFRADIAPHRAGMATIC HODGKIN’S LYMPHOMA: A UNIQUE IDENTITY	6
REFINING THE GENETIC LANDSCAPE OF AGGRESSIVE B-CELL LYMPHOMA BY INTEGRATIVE MOLECULAR ANALYSIS	6
IRF4 GENE REARRANGEMANT IN PEDIATRIC AND ADOLESCENT PATIENTS DIAGNOSED WITH LARGE B-CELL LYMPHOMA	6

A NOVEL CYTOKINE-ANTIBODY FUSION PROTEIN, N-820, TO ENHANCE THE FUNCTIONS OF EX-VIVO EXPANDED NATURAL KILLER CELLS AGAINST BURKITT LYMPHOMA	6
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution	6
Topic: AS01-Diagnosis/AS01b-Flow cytometry	6
Topic: AS01-Diagnosis/AS01a-Cytomorphology	6
Hematogones with light chain restriction: A potential diagnostic pitfall when using flow cytometry analysis to assess bone marrow specimens	6
INTERIM ANALYSIS OF CHINA-NET CHILDHOOD LYMPHOMA GROUP CNCL-NHL-2017 PROTOCOL IN THE TREATMENT OF CHILDREN WITH DIFFUSE LARGE B-CELL LYMPHOMA	6
SHEDDING LIGHT ON GREY ZONE LYMPHOMA	6
NON-HODGKIN LYMPHOMA PRESENTING WITH SPINAL CORD COMPRESSION: A POPULATION-BASED ANALYSIS ON THE NHL-BFM STUDY GROUP	6
TARGETED THERAPY INCREASES PD-L1 PROTEIN EXPRESSION IN CELL LINES OF MEDIASTINAL LYMPHOMA	6
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations	6
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations	6
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations	6
POST-TRANSPLANT LYMPHOPROLIFERTIVE SYNDROME IN CHILDREN AND ADOLESCENTS UNDERGOING TRANSPLANTS HEPATIC AND RENAL: EPIDEMIOLOGICAL, DIAGNOSTIC AND THERAPY IN A BRAZILIAN	6
EFFICACY AND SAFETY OF SEQUENTIAL DIFFERENT B CELL ANTIGEN-TARGETED CAR T-CELL THERAPY FOR PEDIATRIC REFRACTORY/ RELAPSED BURKITT LYMPHOMA WITH SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT	6
AN UNUSUAL PRESENTATION OF A RARE PEDIATRIC DISEASE	6
SOX11 AND EPSTEIN–BARR VIRUS MAY SUBSTITUTE EACH OTHER IN EARLY PATHOGENESIS OF BURKITT LYMPHOMA	6
PLASMA S-Evs miRNAs IN PEDIATRIC B-mALL: TUMOR BIOMARKERS AND TRANSFORMING FACTORS OF BONE MARROW NICHE	6
Topic: AS08-Treatment/AS08e-New developments - Preclinical studies	6
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations	6
Topic: AS02-Epidemiology	6
Editorial Board	5
MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner	5
A systems genetics approach delineates the role of Bcl2 in leukemia pathogenesis	5
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study	5
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment	5
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations	5
PRELIMINARY RESULTS OF A PHASE 2 TRIAL OF OBINUTUZUMAB, IN COMBINATION WITH IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (O-ICE) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH RELAPSED/ REFRACTORY MATURE B-C	5
Presentation name: MDS progression to AML	5
Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia	5
Association of insurance disparities and survival in adults with multiple myeloma: A non-concurrent cohort study	5
Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis	5
DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphoma	5
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation	5
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment	5
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations	5
Presentation name: Hereditary predisposition to MDS	5
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche	5
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis	5
Prognostic role of TNF alpha, LT alpha, MDR1 and codon 72 Tp53 gene polymorphisms on multiple myeloma Egyptian patients	5
Effects of conventional interventions on early-stage primary cutaneous marginal zone lymphoma: A population-based study	5
PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation	5
Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents	5
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation	5
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations	5
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation	5
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine	4
Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment	4
Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia	4
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial	4
Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma	4
COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience	4
Editorial Board	4
Discrepancy in transcriptomic profiling between CD34 + stem cells and primary bone marrow cells in myelodysplastic neoplasm	4
Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines	4
Acquired alpha thalassemia associated with myeloid malignancy: A systematic literature review	4
NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma	4
Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy	4
A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis	4
The role of splenectomy in management of splenic B-cell lymphomas	4
Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms	4
Editorial Board	4
Clonal hematopoiesis: Molecular and clinical implications	4
Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy	4
Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope	4
Elevated expression of interleukin 16 in chronic lymphocytic leukemia is associated with disease burden and abnormal immune microenvironment	4
Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events	4
Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1	4
Causal role of genetically predicted 731 immune cell phenotypes in chronic lymphatic leukemia: A bidirectional Mendelian randomization study	4
A rare BCR-ABL1 transcript in chronic myeloid leukemia: Case report and literature review	4
Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts	4
Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations	4
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study	4
Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group	4
Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA	4
The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis	4
A new prognostic risk model for acute myeloid leukemia patients based on telomere-related genes	4
Concurrent myelodysplasia and monoclonal B lymphocytosis in VEXAS syndrome	4
A systematic review of primary gastric diffuse large B-cell lymphoma: Clinical diagnosis, staging, treatment and prognostic factors	4
Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia	4
Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future	4

Whole-genome optical mapping to elucidate myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions	4
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database	4
MD-1 downregulation is associated with reduced cell surface CD180 expression in CLL	4
Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis	4
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling	4
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONGITUDINAL PREVALENCE OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IN BREAST AND OVARIAN CANCER PATIENTS	3
Two distinct syndromic children with T-acute lymphoblastic leukemia: Noonan syndrome and Sotos syndrome	3
Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell	3
Post-transplant cyclophosphamide: A double-edged sword?	3
A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia	3
Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma	3
Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy	3
The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis	3
Treatment of lymphomas via regulating the Signal transduction pathways by natural therapeutic approaches: A review	3
Changing frontline AML treatment patterns from 2013 to 2022	3
Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia	3
MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients	3
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: TET2 MUTATIONAL STATUS AFFECTS MYELODYSPLASTIC SYNDROME EVOLUTION TO CHRONIC MYELOMONOCYTIC LEUKEMIA	3
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CMML PATIENTS WITH LOW EXPRESSION OF TP53 POINT TO AML TRANSFORMATION	3
Topic: AS03-Health Economics & Outcome Research/AS03c-Efficacy outcome measures: STATINS IMPROVE OVERALL- AND LEUKEMIA FREE- SURVIVAL FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES; A RETROSPECTIVE S	3
CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells	3
Topic: AS02-Epidemiology: CHIP AND INCIDENTAL ANAEMIA IN PATIENTS REFERRED TO SYDNEY GERIATRIC CLINICS FOR FRAILTY ASSESSMENT – A PROSPECTIVE STUDY	3
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation	3
Editorial Board	3
Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia	3
VEXAS syndrome in a patient with DDX41 germline predisposition syndrome	3
Exosome-derived miR-let-7c promotes angiogenesis in multiple myeloma by polarizing M2 macrophages in the bone marrow microenvironment	3
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML – A systematic review	3
Circ_SEC61A1 contributes to the progression of multiple myeloma cells via regulating miR-660-5p/CDK6 axis	3
Editorial Board	3
Single vs double umbilical cord blood transplantation in acute leukemia: Systematic review and meta-analysis	3
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: ABERRANT IMMUNE LANDSCAPE IN BONE MARROW OF HIGH-RISK MYELODYSPLASTIC SYNDROME PATIENTS	3
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): MAMMALIAN DIAPHANOUS-RELATED FORMIN 1 IS REQUIRED FOR MAINTAINING HEMATOPOIETIC STEM CELL QUIESCENCE AND SURVIVAL VIA REGU	3
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: KENNEDY’S DISEASE AND MYELODISPLASTIC SYNDROME: A POSSIBLE NEW ENTITY IN MYELOID NEOPLASM GERMLINE PREDISPOSITION. A CASE REPO	3
Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib	3
Editorial Board	3
A new sequential conditioning regimen based on CPX- 351/Vyxeos (“Vyx-Seq”) in patients with higher risk myelodysplastic syndromes	3
Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions	3
Procalcitonin and C-reactive protein predict infection in hematopoietic stem cell transplantation patients	3
Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy	3
Outcomes of triple-class refractory multiple myeloma patients at a single clinic: A retrospective study	3
Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives	3
Editorial Board	3
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: ROUTINE INFLAMMATORY MARKERS ARE ELEVATED IN MYELODYSPLASTIC SYNDROMES AT PRESENTATION	3
TARGETING DYSERYTHROPOIESIS IN CLINICAL PRACTICE	2
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells	2
MATURE B CELL NON-HODGKIN LYMPHOMA TREATMENT AND RESULTS IN A RETROSPECTIVE COHORT OF CHILDREN AND ADOLESCENTS TREATED BETWEEN 2016 AND 2020 IN LATIN AMERICA	2
ALK+ ALCL EVADES IMMUNE SURVEILLANCE THROUGH NPM-ALK-DRIVEN EPIGENETIC REPRESSION OF Cd48	2
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): PATHOGENIC VARIANTS RELATED TO HEMATOLOGIC MALIGNANCIES CONTRIBUTE TO THE DIFFERENTIAL DIAGNOSIS OF CYTOPENIA	2
AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts	2
ACCELERATED RNA SPLICING DYNAMICS DURING ERYTHROID DIFFERENTIATION AMPLIFY MIS-SPLICING IN SF3B1-MUTANT MDS-RS	2
Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?	2
CTX-712, A NOVEL SPLICING INHIBITOR TARGETING MYELOID NEOPLASMS	2
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN THE TREATMENT OF MDS PATIENTS. A SINGLE CENTER EXPERIENCE	2
PRE-TRANSPLANT TREATMENT OF HEPATISPLENIC T-CELL LYMPHOMA (GAMMA-DELATA): A PEDIATRIC CASE REPORT	2
Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): UNDERSTANDING CMML BIOLOGY BY INTEGRATIVE ANALYSIS OF EXOME SEQUENCING, RNA SEQUENCING, AN	2
OMITTING RADIATION IN YOUNG ADULT FEMALES WITH HODGKIN’S DISEASE, IS THERE AN IMPACT ON OUTCOME??	2
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPACT OF IPSS-M IMPLEMENTATION IN REAL-LIFE CLINICAL PRACTICE	2
PEDIATRIC BIPHENOTYPIC NON-HODGKIN LYMPHOMA: A CASE REPORT AND REVIEW OF LITERATURE	2
Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis	2
GERMLINE CHEK2 MUTATED MDS PATIENTS	2
TRANSCRIPTION AND REPLICATION IMPAIRMENTS DRIVING MYC-INDUCED B AND T CELL LYMPHOBLASTIC LYMPHOMAS	2
Poster Pitch Presentations	2
OBINUTUZUMAB (GA101) VS. RITUXIMAB SIGNIFICANTLY ENHANCES CELL DEATH, ANTIBODY-DEPENDENT CYTOTOXICITY AND IMPROVES OVERALL SURVIVAL AGAINST CD20+ PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) IN A XENOGR	2
Editorial Board	2
Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution	2
Topic: AS01-Diagnosis/AS01a-Cytomorphology: AUTOMATED DIGITAL TOOL FOR MDS AND MDS/MPN CLASSIFICATION USING WHO AND ICC: INTERNATIONAL GUIDELINES WORKING GROUP ON MDS DIAGNOSIS, PROGNOSIS, AND GERMLIN	2
Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): INCORPORATION OF MOLECULAR PROFILE TO A COHORT OF ALLOGRAFTED MYELOMONOCITIC LEUKEMIA PATI	2
HETEROCHROMATIN CHANGES IN HSCS FROM CMML PATIENTS CONFER SENSITIVITY TO THE COMBINATION OF G9A/GLP INHIBITORS AND DNA HYPOMETHYLATING AGENTS VIA DEREPRESSION OF RETROELEMENTS	2
Editorial Board	2
WHOLE GENOME SEQUENCING REVEALS MOLECULAR HETEROGENEITY OF DIFFUSE B-CELL LYMPHOMAS IN CHILDREN WITH NIJMEGEN BREAKAGE SYNDROME	2
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC	2
A RARE CASE OF PRIMARY OCULAR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN A BRAZILIAN CHILD	2
Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): TET2/SRSF2 STATUS AND THROMBOSIS ARE RELEVANT FOR PROGNOSIS IN CHRONIC MYELOMONOCYTIC LEUK	2
PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES	2
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INCREASED DNA-CELL-CYCLE S-PHASE FRACTION IS RELATED TO INCREASED INCIDENCES OF IMMATURE MYELOID CELLS AND HIGH IPSS-R RI	2
FDG-PET/CT IMAGING IN PEDIATRIC PRECURSOR B-CELL LYMPHOBLASTIC LYMPHOMA (BCP-LBL) SHOWS BONE (MARROW) INVOLVEMENT IN A VAST MAJORITY OF PATIENTS	2
COMBINED BORTEZOMIB AND VENETOCLAX TARGETS THE PRO-SURVIVAL FUNCTIONS OF LATENT VIRAL PROTEINS IN EPSTEIN-BARR VIRUS-DRIVEN LYMPHOPROLIFERATIVE DISEASES	2
MCL-1 INHIBITORS INDUCES APOPTOSIS IN VITRO IN BURKITT LYMPHOMA CELL LINES AND INHIBITS IN VIVO BURKITT LYMPHOMA PROGRESSION	2
OUTCOME OF CHILDREN TREATED FOR RECURRENT EPSTEIN-BARR VIRUS (EBV)-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD)	2
CLINICAL SPECTRUM OF PRECURSOR B-CELL LYMPHOBLASTIC MALIGNANCIES: A LARGE COHORT STUDY OF 364 PEDIATRIC PATIENTS	2
IMPACT OF RITUXIMAB ON IMMUNE STATUS FOLLOWING THERAPY IN CHILDREN AND ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN LYMPHOMA: RESULTS OF THE INTER-B-NHL RITUX 2010 TRIAL	2
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): MUTATIONS OF SF3B1 GENE AND ITS SIGNIFICANCE ON PATIENTS WITH MYELODYSPASTIC SYNDROMES (MDS)	2
Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience	2
TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS	2
Germline predisposition to clonal hematopoiesis	2
EPSTEIN-BARR VIRUS ORCHESTRATE THE TUMOR MICROENVIRONMENT OF BURKITT LYMPHOMA	2
Topic: AS09-Quality of life-Disease experiences: ANEMIA OF CHRONIC DISEASE IN THE ELDERLY: EVALUATION OF HEPCIDIN EXPRESSION AND ITS RELATIONSHIP WITH PROINFLAMMATORY CYTOKINES AND CLINICAL AND LABORA	2
FULMINANT, EBV DRIVEN PLASMACYTIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) WITH LOSS OF 1P AND GAIN OF TP53/CEP17 AND IGH BONE MARROW INVOLVEMENT AFTER LIVER TRANSPLANT IN 17-MONTH OLD BOY	2
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) P	2
MOLECULAR GENETICS ANALYSIS OF B-CELL PRECURSOR LYMPHOMA IN PEDIATRIC AND ADOLESCENT PATIENTS REVEALS HIGH FREQUENCY OF KMT2A TRANSLOCATIONS	2
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: HIGH PREVALENCE OF IDIOPATHIC DYPSLASIA OF UNDETERMINED SIGNIFICANCE (IDUS) AND CLONAL HEMATOPOIESIS OF	2
REFRACTORY B-LYMPHOBLASTIC LYMPHOMA SUCCESSFULLY TREATED WITH TISAGENLECLEUCEL AND CONSOLIDATIVE STEM CELL TRANSPLANT	2
5′ Rapid amplification of cDNA ends (5′RACE): A simpler method to analyze immunoglobulin genes and discover the value of the light chain in chronic lymphocytic leukemia	2
Editorial Board	2